1590P - Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)

Background

The LEGACy project aims to improve personalized medicine for gastric cancer in EU and LATAM populations. A hospital-based registry was implemented to compare these populations as a potential tool to plan prevention and treatment strategies providing real-world data.

Methods

A retrospective observational cohort design was used. Survival estimates were determined using actuarial Kaplan-Meier curves. Comparison was performed with the loge-rank test, and differences were considered statistically significant for P values .05.

Results

A total of 689 patients diagnosed with GC from 11/2018 to 04/2021 were included. Country and clinical characteristics are shown in the table. Both cohorts had the body as the most common site reported (34.4% for EU and 51% for LATAM). The most used method for staging was computed tomography for both cohorts, but 6.9% of the LATAM population had a PET/TC instead. The staging at diagnose for LATAM was lower than for the EU population (2.8% and 17.4% respectively). Intestinal histological subtype was the most common (41.9% and 46.3% reported by EU and LATAM), while diffuse subtype was 44.9% for LATAM and 21.3% for EU population. Among patients tested for HER2, 12.5% were positive in the EU cohort and 13.8% in the LATAM cohort. For both cohorts, the most common site of HER2 positive was the GOJ. Surgery was reported in 43.4% of EU population and 48.9% in the LATAM cohort. Systemic treatment with curative intention was indicated in 50.7% in the EU cohort and 46.4% of the LATAM cohort. The most frequent scheme indicated was platinum-based (42.6% and 84.8% for EU and LATAM). Considering both cohorts only 14.4% of the patients got a 2° line of treatment and 3% of the patients received a 3° line. After using cox regression analysis, no difference in overall survival was reported, with a median of 10.9 months.

Table: 1590P

Conclusions

Although the limitations of hospital-based registry analysis, this study have provided valuable insights into clinical characteristics and treatment approaches of EU and LATAM populations.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

European Union’s Horizon 2020.

Disclosure

All authors have declared no conflicts of interest.